Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Exubera Post-Market Training Needs Greater Emphasis – Cmte.

Executive Summary

Pfizer/Sanofi-Aventis' post-marketing training program for administering the inhaled insulin powder Exubera with a novel mechanical inhaler needs greater focus, FDA's Endocrinologic & Metabolic Drugs Advisory Committee said in a Sept. 8 review
Advertisement

Related Content

Pfizer’s Exubera Cost-Effectiveness Estimates Not Realistic, U.K.’s NICE Says
Pfizer Holding Its Breath On Exubera DTC Advertising To Focus On Education
Exubera Education, Complicated Manufacturing Impacting Launch Timeline
Pfizer Exubera Has Mid-Year Launch Trigger, Heavy Dose Of Instructions
Exubera Lung Test Will Be Advised Until More Data Is Collected, FDA Says
Exubera’s Post-Marketing Safety Program Is Industry Model – Pfizer’s Ryder
Inhaled Insulin Manufacturers Find Size Matters After Exubera Cmte. Review
Pfizer/Sanofi’s Exubera May Need More Data In Asthma, COPD Patients
Pfizer/Sanofi’s Exubera May Need More Data In Asthma, COPD Patients
Pfizer/Aventis File For Exubera In Europe; No Timeline Yet On U.S. NDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS046335

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel